PHARMA

OM Pharma is a **special animal**

- Unique **fully-fledged pharma** in Geneva since 1937
- **Private**, controlled by one shareholder
- **350 MCHF** long-standing current business
- **250 MCH** investment in last 5 years
- **100** countries where we treat 16M patients
- **500** people & 90 partnerships (ca. 1’500 reps)
- One major opportunity: **US market entry**
- One focus: **bacterial lysates**

OM Pharma's global footprint: 100 countries



BRONCHO-VAXOM®
URO-VAXOM®
DOXIUM®
Dicynone®

TRITTICO®
SYMFONA®
XEPLION®
TREVICTA®
Lithiofor®
Jarsin® 450
Sedonium®
PROLASTIN®
FOSTER
Trimbow®
BRONCHO-VAXOM®
BRAMITOB®
Quinsair®
Mucofor®
URO-VAXOM®
Furadantin®
SabCaps®
Oprane®
Kengrexal®
ENVARSUS®
Cleviprex®
Doxium
Dicynone®
mg5
Viferol D3®
Diamox®
Hepa-S®
Mutaflor®
Faros®

Largest **bacterial lysates** plant in the world

One focus: **bacterial lysates**

- Medicines made from **selected strains of bacteria** that are fragmented and inactivated
- Manufactured by OM Pharma **since 1930**
- Bacterial lysates **train the immune system**, replicating the microbial stimulation observed in natural environments

Why focus on bacterial lysates *today*?

Exposure to **microbial diversity** has dramatically declined



↗ **Infections**
Atopic diseases

↗ **Antibiotic use**
Corticosteroid use

↗ **AMR**
“Corticophobia”

Note: while prevalence is quite stable globally, there are growing concerns about RTI management: COVID and post-COVID rebounds, aging populations with chronic diseases, environmental factors such as pollution, and rising antimicrobial resistance.

“Farm effect”: compelling evidence for exposure to biodiversity

RTI: respiratory tract infections

Illi S, et al. J Allergy Clin Immunol. 2012 Jun;129(6):1470-7.e6. (results from GABRIEL study); Loss G, et al. J Allergy Clin Immunol. 2015 Jan;135(1):56-62 (results from PASTURE study); Vercelli D. Semin Immunol. 2023 Jul;68:101779.

Bacterial lysates help replicate **natural microbial stimulation**



OM-85 is indicated in the prevention of recurrent Respiratory Tract Infections

Data in children; in adults, OM-85 reduced RTIs by 33% and related exacerbations by 41.2% in adults with asthma or allergic rhinitis. UTI: urinary tract infections.

Ref.: Esposito S, et al. J Transl Med. 2019;17:284; de Boer GM, et al. Eur Respir Rev. 2020;29:190175. Koatz AM, et al. Lung. 2016;194:687-97. Naber KG, et al. Int J Antimicrob Agents. 2009;33:111-9; Schulman CC, et al. J Urol. 1993;150(3):917-21.

1) Exploit current potential in **infection prevention**

- Current indication is prevention of recurrent **respiratory and urinary tract infections**
- Currently 230 M$ (in-market) in 80 countries with a **4 B$ potential***
- Huge unmet need in prevention of infection (**pandemics**) and antimicrobial resistance (**AMR**)
- Main challenge is societal, medical and individual **acceptance of prevention**
- Extensive investment in **data** generation and **education** (Imm'Uni™)

* in-market sales; extrapolation of current PT and SK penetration to all existing markets

Main current **infection prevention** studies

OM-85 oral in prevention of **respiratory tract infection RWE**
REACH (RWE results)
→ Q2 **26**

OM-85 oral in prevention of **respiratory tract infection 6-12y**
TIGER (Ph. 4 results)
→ Q2 **26**

OM-85 oral in prevention of **respiratory tract infection 6m-5y**
BEAR (Ph. 4 results)
→ Q4 **26**

OM-85 oral in prevention of **respiratory tract infection 18+**
OLDER (IT), LION (CN) (Ph. 4 results)
→ **27 28**

2) Shift the paradigm in **asthma prevention**

- Microbial exposure helps prevent the development of **asthma** and **allergies** (known as the "**hygiene hypothesis**" or "**farm effect**")
- Solid evidence that **OM-85** can mimic the "farm effect"
- **Wheezing** (asthma-like symptom in childhood) is our targeted indication to enter **US market**
- Potential is **above 2 B$** in the US only
- **New data** in 2026 to progress toward **US registration**
- Clinical programmes with both **oral** and **intranasal** formulations

Available early evidence in **wheezing** and **asthma**

↓ 38% WHEEZING ATTACKS IN PRESCHOOL CHILDREN 1-6 YEARS OLD[1]



↓ 50% ASTHMA ATTACKS IN CHILDREN 5-15 YEARS OLD[2]



OM-85 is indicated in the prevention of recurrent Respiratory Tract Infections

ICS: Inhaled corticosteroid

1. Razi CH, et al. J Allergy Clin Immunol 2010;126:763–769: 2 Lu Y. et al. Pharmacology 2015;95:139–144 . These 2 studies are included in the De-Boer 2020 meta-analysis resulting in a global reduction of -47%.

Main **wheezing** and **asthma** pipeline studies



Funding, partnering and **IPO**

Self-funding and/or **investors** and **partners** to fund Ph. 3 and launch

IPO based on positive Ph. 3 results to fund launch?

IPO based on positive traction on US market to fund WW expansion?

Ph.2 results

Ph.3 results

Launch

Peak sales

PHARMA